Eyetech raises revenue forecast for Macugen

Remaining bullish about its prospects for Macugen, a treatment for wet, age-related macular degeneration, Eyetech has raised its sales forecast for the drug. Eyetech, which markets the drug with Pfizer, raised its sales forecast by $40 million for the year. Eyetech shares advanced on the news.

"Macugen's launch has exceeded our initial expectations and we are pleased that Macugen is quickly establishing itself as a foundation therapy for neovascualar AMD," said David Guyer, the company's CEO, in a statement.

- read this article from MarketWatch for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.